Analyst Rating for CRISPR Therapeutics


CRISPR Therapeutics CRSP saw the following analyst ratings for the past quarter:

quickly bit bullish Moody bit bearish recession
overall rating 2 5 6 0 0
last 30d 0 0 1 0 0
1m ago 0 1 2 0 0
2m ago 2 4 3 0 0
3m ago 0 0 0 0 0

These 13 analysts have an average target price of $95.15, while CRISPR Therapeutics has a current price of $63.76, indicating an upward move.

Below is a summary of how these 13 analysts rated CRISPR Therapeutics over the last 3 months. The higher the number of bullish ratings, the more positive analysts rate the stock, and the higher the number of bearish ratings, the more negative analysts rate the stock.

This represents a 19.59% drop from the current average price target of $118.33.

Analysts are experts on banking and financial systems who typically report on specific stocks or within defined sectors. These people research a company’s financial statements, attend conference calls and meetings, and speak with relevant insiders to determine what is called an analyst rating for a stock. Typically, analysts rate each stock once a quarter.

Some analysts also provide predictions for helpful metrics like earnings, sales, and growth forecasts to provide further guidance on what to do with specific tickers. It’s important to note that stock and sector analysts are both experts and people and can only assess their beliefs for traders.

This article was created by Benzinga’s Automated Content Engine and is editor-reviewed.



Please enter your comment!
Please enter your name here